Medicinal composition of nimustine and its progression agent
A synergist and drug technology, applied in drug combinations, medical preparations containing active ingredients, anti-tumor drugs, etc., can solve problems such as unclear effects, achieve the effects of convenient drug injection, reduce complications, and reduce costs
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Examples
Embodiment 1
[0130] Put 70 mg of polylactic acid (PLA) with a molecular weight of 20,000-40,000 as a pharmaceutical excipient into a container, add 100 ml of organic solvent dichloromethane to dissolve and mix well, add 10 mg of nimustine and 20 mg of anastrozole, and re-shake Dry in vacuo to remove the organic solvent. Shake again and dry in vacuo to remove the organic solvent. The dried drug-containing solid composition was frozen and pulverized to make a micropowder containing 10% nimustine and 20% anastrozole, and then suspended in physiological saline containing 1.5% sodium carboxymethylcellulose to prepare the corresponding Suspension-type sustained-release injection with a viscosity of 480cp-560cp (at 25°C-30°C). The subcutaneous release time is 35-45 days.
Embodiment 2
[0132] Put 75 mg of polylactic acid (PLA) with a molecular weight of 30,000-50,000 as a pharmaceutical excipient into a container, add 100 ml of organic solvent dichloromethane to dissolve and mix well, add 10 mg of nimustine and 15 mg of pemetrexed, and shake again Then dry in vacuo to remove the organic solvent. The dried solid composition is shaped immediately, subpackaged and then sterilized by radiation to obtain an anticancer in vivo implant for treating solid tumors with 10 mg of nimustine and 15 mg of pemetrexed. The subcutaneous release time is 40-45 days.
Embodiment 3
[0134] Put 80 mg of polylactic acid (PLA) with a molecular weight of 25,000-40,000 as a pharmaceutical excipient into a container, add 100 ml of organic solvent dichloromethane to dissolve and mix well, add 5 mg of nimustine and 15 mg of edoxifene, and shake again Then dry in vacuo to remove the organic solvent. The dried solid composition is shaped immediately, subpackaged and then sterilized by radiation to obtain an anticancer in vivo implant containing 5% nimustine and 15% edoxifene for treating solid tumors. The subcutaneous release time is 30-40 days.
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com